
News|Articles|September 1, 2009
FDA Pipeline preview, September 2009 (cethromycin, pegloticase, guanfacine, denosumab, apaziquone, TZP-102, beclomethasone 17,21-dipropionate)
Recent FDA action (through September 2009) related to cethromycin, pegloticase, guanfacine, denosumab, apaziquone, TZP-102, and beclomethasone 17,21-dipropionate
Advertisement
Complete response
Recommended for approval
Not recommended for approval
Orphan drug designation
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Transparency paves the way for lower costs and equitable access
2
New self-injectable biologics promise cost savings and patient convenience
3
Stanford scientists find link between Epstein-Barr virus and lupus
4
Evaluating Chronic Kidney Disease as a Risk Factor for Cardiovascular Disease: Written Recap
5






















































